Results 111 to 120 of about 47,575 (169)

Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trial. [PDF]

ERJ Open Res
Sitbon O, Agoston G, Badagliacca R, Hajnalka Balint O, Blanco I, Coman IM, Ewert R, Halank M, Jansa P, Kopeć G, Kurzyna M, Tenes A, Opitz C, Plácido R, Přeček J, Riou M, Steringer-Mascherbauer R, Țilea I, Lang IM.   +18 more
europepmc   +1 more source

A descriptive cross-sectional study to evaluate the Generic Drug User Fee Act: A boon or loss to the Indian generic pharmaceutical industry

Journal of Applied Pharmaceutical Science, 2019
openaire   +1 more source

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with <i>MET</i> exon 14 skipping mutated non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Lu S, Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, Zhang L, Bai C, Fang J, Cao L, Zhao Y, Yu Y, Shi M, Zhong D, Li F, Duanmu W, Wang Y.   +31 more
europepmc   +1 more source

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. [PDF]

Breast Cancer Res Treat
Masuda N, Yasojima H, Bando H, Yamanaka T, Shigematsu H, Takahashi M, Nagai SE, Ito M, Aruga T, Tokiwa M, Imoto S, Nakamura R, Ishiguro H, Kawabata H, Saji S, Haga H, Morita S, Toi M.   +17 more
europepmc   +1 more source

Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain? [PDF]

Breast
Polho GB, Shinkado YR, Murazawa LK, Oliveira VV, Pinheiro VR, Labanda DDCP, Barroso-Sousa R, Carvalho Barros LR, Testa L, Bonadio RC.   +9 more
europepmc   +1 more source

Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial.

JAMA Neurol
Kimura K, Nishiyama Y, Iwasaki YK, Shimizu W, Toyoda K, Sakamoto Y, Katano T, Yamamoto T, Takeuchi M, Kumagai K, Tsuto K, Sugi K, Kusano K, Koga M, Okubo S, Sato T, Hamaguchi H, Yoshida A, Kuriki A, Tanno K, Kitagawa K, Hagiwara N, Daida H, Iguchi Y, Fujimoto S, Miyamoto S, Fukuzawa M, Sugimoto M, Takita A, Otsuka T, Okumura K.   +30 more
europepmc   +1 more source

Alzheimer’s Disease blood biomarkers measured through remote capillary sampling correlate with cognitive performance in older adults

Corbett A, Sander-Long M, Ashton N, Huber H, Zetterberg H, Montoliu-Gaya L, Bateman F, Ballard C.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Charging for hospital pharmaceutical services: Product cost, per diem fees and fees for special clinical services

American Journal of Health-System Pharmacy, 1979
A method of charging for pharmaceutical services is described which includes the cost of drug products, dispensing fees for intravenous drug admixtures, per diem fees for basic dispensing and clinical services (according to patient type), and fees for special clinical services.
W E, Smith, J W, Weiblen
openaire   +2 more sources

Charging for hospital pharmaceutical services: Combined product-service per diem fees

American Journal of Health-System Pharmacy, 1979
The development of a per diem hospital pharmacy charge is reviewed after five years of use. The itemized pharmacy charges for every tenth patient (total of 250 patients) admitted to the hospital during a three-month period were studied to determine the average daily charges for drugs and pharmaceutical services. Six categories of rates were designated,
I, Dirks, F J, Pang
openaire   +2 more sources